Citation tools
"64Cu-DOTATATE PET/CT for Imaging Patients with Known or Suspected Somatostatin Receptor–Positive Neuroendocrine Tumors: Results of the First U.S. Prospective, Reader-Masked Clinical Trial." Journal of Nuclear Medicine
61.6
(2020):
890-896.
Web. 19 April. 2024.